Article Text

PDF
Short report
Bilateral vestibular schwannomas in older patients: NF2 or chance?
  1. D G Evans1,
  2. S Freeman2,
  3. C Gokhale1,
  4. A Wallace1,
  5. S K Lloyd2,
  6. P Axon3,
  7. C L Ward4,
  8. S Rutherford4,
  9. A King4,
  10. S M Huson1,
  11. R T Ramsden2
  12. on Behalf of the Manchester NF2 service
  1. 1Genomic Medicine, University of Manchester, Manchester Academic Health Science Centre, Institute of Human Development, Central Manchester NHS Foundation Trust, Manchester Royal Infirmary, Manchester, UK
  2. 2Department of Otolaryngology, University of Manchester, Manchester Academic Health Science Centre, Institute of Human Development, Central Manchester NHS Foundation Trust, Manchester Royal Infirmary, Manchester, UK
  3. 3Depertment of Otolaryngology, Addenbrooke's Hospital Cambridge, Cambridge, UK
  4. 4Department of Neurosurgery, Salford Royal NHS Foundation Trust, Manchester, UK
  1. Correspondence to Professor D Gareth R Evans, Genomic Medicine, St Mary's Hospital, Oxford Road, Manchester M13 9WL, UK; gareth.evans{at}cmft.nhs.uk

Abstract

Background Neurofibromatosis type 2 (NF2) is an autosomal dominant condition with high spontaneous mutation rate which predisposes to the development of multiple nerve sheath tumours (schwannomas), meningiomas and ependymoma. The cardinal feature and main diagnostic criterion for the diagnosis of NF2 remains the development of bilateral vestibular schwannoma (BVS). With increasing use of MRI screening the possibility of a ‘chance’ diagnosis of BVS has been mooted with a potential frequency of one in two million people in their lifetime. Until now, however, no evidence for such an event has been published. We aimed to demonstrate that chance occurrence can occur and to estimate its frequency among those with just BVS late in life.

Methods Two vestibular schwannomas from the same patient were DNA sequenced and underwent loss of heterozygosity analysis.

Results We show that a man who developed BVS, at ages 52 and 67 years developed these tumours sporadically by demonstrating that there were no molecular events in common between the two tumours. Furthermore from a database of over 1200 patients with NF2, we have estimated that ∼25% of cases of BVS over 50 years and 50% over 70 years of age where no other features of NF2 are present represent a chance occurrence rather than due to an underlying mosaic or constitutional NF2 mutation.

Conclusions Patients presenting with BVS later in life should be appraised of the potential likelihood they may not have NF2 and the resultant further reduction in risks of transmission to offspring.

  • Cancer: CNS
  • Diagnosis
  • Epidemiology
  • Genetic epidemiology

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.